Boston Scientific Corp. announced that it has agreed to acquire Silk Road Medical Inc., a medical device company that specializes in vascular surgical treatments to reduce the risk of stroke. The value of the definitive agreement is $1.16 billion based on a $27.50-per-share price. Silk Road Medical has developed products to facilitate transcarotid artery revascularization (TCAR), a less-invasive alternative to surgical endarterectomy. "The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease," said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific, in a company news release issued Tuesday. "We believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease." The transaction is expected to be complete later this year. Image Credit: rh2010 – stock.adobe.com